Shanghai Pharmaceuticals Holding Co., Ltd. (601607.SH) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 20Aug 25Aug 28Sep 2Sep 7Sep 10Sep 15Sep 18

Key dataSep 18, 2026

OpenCNY 16.08

From 52W high−12.25%

Volume11.81M

Market capCNY 60.04B

P/E (TTM)10.5x

P/S (TTM)0.2x

Div yield3.58%

Key dataSep 18, 2026

Open

CNY 16.08

From 52W high

−12.25%

Volume

11.81M

Market cap

CNY 60.04B

ValuationView details →

P/E (Fwd)

12.6x

EV/EBITDA

7.6x

P/E (TTM)

10.5x

RSI (14)

35.2

MomentumView details →

1D Return

+0.00%

YTD Return

−10.97%

ValuationView details →

P/E (Fwd)

12.6x

P/E (TTM)

10.5x

EV/EBITDA

7.6x

EV/Sales

0.3x

P/S (TTM)

0.2x

P/B (TTM)

0.8x

ProfitabilityView details →

Gross Margin

10.85%

Net Margin

2.02%

EBITDA Margin

4.25%

ROE (TTM)

7.52%

ROA (TTM)

2.47%

Asset Turnover

1.23x

GrowthView details →

Revenue YoY

+4.43%

EPS YoY

+33.60%

FCF YoY

−25.91%

Revenue CAGR 3Y

+6.92%

EPS CAGR 3Y

−1.47%

EBITDA YoY

—

MomentumView details →

1D Return

+0.00%

YTD Return

−10.97%

1Y Return

−11.32%

RSI (14)

35.2

vs 50D SMA

−3.64%

vs 200D SMA

−5.99%

Capital & dividendView details →

Debt/Equity

0.67x

Current Ratio

1.34x

Quick Ratio

1.03x

Div Yield

3.58%

Div Rate

CNY 0.57

Div Growth 1Y

+96.55%

EarningsView details →

EPS (Actual)

CNY 0.65

EPS Surprise

0.00%

Beats (12Q)

0/12

Next Q EPS Est

CNY 0.26

Avg Surprise (4Q)

0.00%

Rev Surprise

−5.86%

Financials snapshotView financials →

Revenue (TTM)

289.15B

Net Income (TTM)

4.76B

Op. CF (TTM)

9.67B

Next earningsOct 23, 2026 →

Latest newsMore news →

Shanghai Pharmaceuticals announced that its subsidiary Shanghai Hefeng Pharmaceutical received the National Medical Products Administration's drug supplementary application approval notice, granting consistency evaluation for its lincomycin hydrochloride injection generic drug.10d ago

Shanghai Pharmaceuticals Holding Co., Ltd. signed a strategic cooperation framework agreement with the Shanghai Institute of Materia Medica of the Chinese Academy of Sciences on September 7, 2026, to collaborate on innovative drug R&D and technology transfer.13d ago

Similar companies

Cencora, Inc.COR Cardinal Health, Inc.CAH Sinopharm Group Co. Ltd.01099.HK Shanghai Pharmaceuticals Holding Co., Ltd02607.HK McKesson CorporationMCK 九州通600998.SH Find similar companies →

Latest newsMore news →

Shanghai Pharmaceuticals announced that its subsidiary Shanghai Hefeng Pharmaceutical received the National Medical Products Administration's drug supplementary application approval notice, granting consistency evaluation for its lincomycin hydrochloride injection generic drug.10d ago Shanghai Pharmaceuticals Holding Co., Ltd. signed a strategic cooperation framework agreement with the Shanghai Institute of Materia Medica of the Chinese Academy of Sciences on September 7, 2026, to collaborate on innovative drug R&D and technology transfer.13d ago Shanghai Pharmaceuticals' subsidiary Shanghai Hefeng Pharmaceutical received NMPA approval for promethazine hydrochloride injection to pass generic consistency evaluation.27d ago